Why Novan Shares Are Surging Today

Novan Inc (NASDAQ:NOVN) shares are trading higher by 59% at $14.37 Friday morning after the company reported the B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved statistical significance for the primary endpoint and no serious adverse events were reported.

Novan is a clinical-stage biotechnology company that provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases.

Novan's clinical-stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.